Evidence map›Paper›PMID 42311698›Full record

ArticleAdvances in hematology2026

Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study.

M Di Cecca, Bongarzoni V, Garzia M, Fazio F, Tomarchio V, Barilà G, Liberatore C, Rago A, Rossini B, Rocco S and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

M Di CeccaUnit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy, unicampus.it.ORCID https://orcid.org/0009-0003-0800-5092
Bongarzoni VDepartment of Hematology, San Giovanni-Addolorata Hospital, Rome, Italy, hsangiovanni.roma.it.
Garzia MHematology and Stem Cell Transplant Unit, San Camillo Forlanini Hospital, Rome, Italy, scamilloforlanini.rm.it.
Fazio FDepartment of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0003-4187-8912
Tomarchio VUnit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, Fondazione Policlinico Universitario Campus Bio Medico, Rome, Italy.
Barilà GHematology Unit, San Bortolo Hospital, Vicenza, Italy, ulssvicenza.it.ORCID https://orcid.org/0000-0003-3430-6115
Liberatore CHematology Unit, Department of Oncology and Hematology, Santo Spirito Hospital, Pescara, Italy.
Rago AHaematology Unit, ASL ROMA 1 Santo Spirito Hospital of Rome, Rome, Italy.
Rossini BHaematology, Giovanni Paolo II Hospital, Bari, Italy.
Rocco SDivision of Hematology, Cardarelli Hospital, Naples, Italy, naplesldm.com.
Pisani FHematology and Stem Cell Transplantation Unit, IRCCS National Cancer Institute "Regina Elena", Rome, Italy.
De Padua LHematology Unit, Fabrizio Spaziani Hospital, Frosinone, Italy.
Fiori LHematology and Transplant Unit, Santa Maria Goretti Hospital, AUSL, Latina, Italy, asl.latina.it.
Tafuri M TUnit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, Fondazione Policlinico Universitario Campus Bio Medico, Rome, Italy.
Anaclerico BDepartment of Hematology, San Giovanni-Addolorata Hospital, Rome, Italy, hsangiovanni.roma.it.ORCID https://orcid.org/0000-0001-8626-2324
Cardarelli LHematology and Stem Cell Transplant Unit, San Camillo Forlanini Hospital, Rome, Italy, scamilloforlanini.rm.it.
Scomazzon EHematology Unit, San Bortolo Hospital, Vicenza, Italy, ulssvicenza.it.
Fioritoni FDepartment of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti, Italy, unich.it.
Caravita Di Torritto THaematology Unit, ASL ROMA 1 Santo Spirito Hospital of Rome, Rome, Italy.
Quinto A MHaematology, Giovanni Paolo II Hospital, Bari, Italy.
Palmieri SDivision of Hematology, Cardarelli Hospital, Naples, Italy, naplesldm.com.
Lamanda MHematology and Stem Cell Transplant Unit, San Camillo Forlanini Hospital, Rome, Italy, scamilloforlanini.rm.it.
Tamburini ADepartment of Hematology, San Giovanni-Addolorata Hospital, Rome, Italy, hsangiovanni.roma.it.
Piciocchi AGIMEMA Foundation, Rome, Italy.ORCID https://orcid.org/0000-0001-8648-885X
Petrucci M TDepartment of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Rome, Italy.
Rigacci LUnit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy, unicampus.it.
Annibali OUnit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy, unicampus.it.ORCID https://orcid.org/0000-0002-3095-5313

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic posed significant challenges for patients with hematological malignancies, including multiple myeloma (MM), who experienced increased hospitalization and mortality rates due to frailty and immune suppression. This retrospective, multicenter study aimed to evaluate the impact of antiviral therapies and COVID-19 vaccination doses on clinical outcomes in 206 symptomatic MM patients undergoing active treatment across five Italian regions. The majority (90%) received at least one vaccine dose, and 61% were treated with antiviral agents (nirmatrelvir/ritonavir, molnupiravir, or remdesivir). Of the cohort, 90% were vaccinated, with 89% receiving ≥ 3 doses, and 61% received antiviral agents (nirmatrelvir/ritonavir, molnupiravir, or remdesivir). Patients vaccinated with ≥ 3 doses showed significantly reduced infection severity (

Indexed as

COVID-19multiple myelomanirmatrelvir/ritonavirremdesivirvaccines

Identifiers

PMID42311698
PMCPMC13269165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.